West Pharmaceutical Services Inc
WST- Exchange
- NYSE
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0000105770
In the last 90 days, West Pharmaceutical Services Inc insiders filed 0 open-market purchases and 2 sales; 834 institutions reported holding it in 13F filings for Q2 2026, worth $25.2B in total; Gates Foundation Trust is the only superinvestor holding it.
13F holders, Q2 2024
Institutional positions in West Pharmaceutical Services Inc as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 778
- +10 vs. Q1 2024
- Shares held
- 68.3M
- −58.2K (−0.1%) vs. Q1 2024
- Total value
- $22.4B
- −$4.53B (−16.8%) vs. Q1 2024
- New holders
- 88
- 278 more added
- Sold out
- 78
- 293 more reduced
10 institutions that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting WST on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 834 | $25.2B |
| Q1 2026 | 755 | $17.8B |
| Q4 2025 | 804 | $19.1B |
| Q3 2025 | 758 | $18.0B |
| Q2 2025 | 733 | $15.3B |
| Q1 2025 | 715 | $15.6B |
| Q4 2024 | 747 | $22.9B |
| Q3 2024 | 733 | $20.5B |
| Q2 2024 | 778 | $22.4B |
| Q1 2024 | 778 | $27.0B |
| Q4 2023 | 784 | $24.1B |
| Q3 2023 | 759 | $25.8B |
| Q2 2023 | 735 | $26.0B |
| Q1 2023 | 698 | $24.0B |
| Q4 2022 | 638 | $16.3B |
| Q3 2022 | 638 | $16.9B |
| Q2 2022 | 657 | $20.6B |
| Q1 2022 | 718 | $28.2B |
| Q4 2021 | 731 | $32.2B |
| Q3 2021 | 672 | $28.5B |
| Q2 2021 | 641 | $24.7B |
| Q1 2021 | 591 | $19.3B |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding West Pharmaceutical Services Inc; share changes are against Q1 2024.